Technology evaluation: GEM-231, Hybridon.
GEM-231 (HYBO-165) is an 18mer hybrid oligonucleotide under development by Hybridon for the potential treatment of cancer. Phase I/II dose-escalation trials of GEM-231 in combination with paclitaxel and docetaxel were ongoing in March 2002. At this time, a phase I/II trial of GEM-231 in combination with irinotecan (CPT-11) was initiated in patients with solid tumors. As of February 2003, Hybridon planned to initiate phase II trials in 2003.
Yeung
Pollen K F
PK
Pharmacokinetics & Metabolism Laboratory, College of Pharmacy, Dalhousie University, Halifax, NS B3H-3J5, Canada. pollen.yeung@dal.ca
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D002460:Cell Line; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009841:Oligonucleotides / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; C425328:GEM231; D009841:Oligonucleotides